{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T21:11:32Z","timestamp":1766697092823,"version":"3.33.0"},"reference-count":12,"publisher":"Wiley","issue":"S322","license":[{"start":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T00:00:00Z","timestamp":1187827200000},"content-version":"vor","delay-in-days":8088,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Psychiatr Scand"],"published-print":{"date-parts":[[1985,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Ten schizophrenic inpatients were each treated with perphenazine enanthate (PE) and perphenazine decanoate (PD). Following a cross\u2010over study design it was possible to evaluate differences in plasma profiles between the two preparations, and to relate these to encountered side effects. All patients had previously been receiving neuroleptic treatment and had been diagnosed according to DSM\u2010III. The dosage and intervals between injections were on an individual basis.<\/jats:p><jats:p>The results indicate that at all dosage levels, the decanoate preparations showed significantly lower peak plasma concentrations of perphenazine. Extrapyramidal side effects and sedation were also less pronounced after the administration of PD. The more even and flat plasma concentrations obtained with PD, may facilitate plasma monitored therapy by using minimum concentration values.<\/jats:p>","DOI":"10.1111\/j.1600-0447.1985.tb08536.x","type":"journal-article","created":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T10:30:46Z","timestamp":1187865046000},"page":"11-14","source":"Crossref","is-referenced-by-count":15,"title":["Perphenazine Decanoate in sesame oil vs. Perphenazine Enanthate in sesame oil: A comparative study of pharmakokinetic properties and some clinical implications"],"prefix":"10.1111","volume":"72","author":[{"given":"Peder","family":"Knudsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars Bolvig","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels\u2010Erik","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,8,23]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1600-0447.1980.tb07083.x","article-title":"Clopenthixol and flupenthixol depot preparations in out\u2010patient schizophrenics","volume":"1980","author":"Dencker S. J.","year":"1980","journal-title":"Acta Psychiatr Scand (Suppl 279)"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1976.tb00647.x"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00432245"},{"key":"e_1_2_1_5_2","first-page":"15","article-title":"Relations between clinical effects and plasma concentrations of perphenazine","volume":"1984","author":"Bolvig Hansen L.","year":"1984","journal-title":"Nord Psykiatr Tidsskr (Suppl 7)"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/978-1-349-06671-1_16","volume-title":"Clinical pharmacology in psychiatry: Neuroleptic and antidepressant research","author":"Bolvig Hansen L.","year":"1983"},{"volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1980","author":"American Psychiatric Association","key":"e_1_2_1_7_2"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9673(01)91797-2"},{"key":"e_1_2_1_9_2","first-page":"1071","article-title":"On the pharmacokinetics of perphenazine: A clinical study of perphenazine enanthate and decanoate","volume":"1984","author":"Larsson M.","year":"1984","journal-title":"Curr Ther Res"},{"key":"e_1_2_1_10_2","first-page":"801","article-title":"Fluphenazine enanthate and fluphenazine decanoate: A comparison of their duration of action and motor side effects","volume":"1975","author":"Praag H. M.","year":"1975","journal-title":"Am J Psychiatry"},{"key":"e_1_2_1_11_2","first-page":"1539","article-title":"Comparison of the incidence and severity of extrapyramidal side effects with fluphenazine enanthate and fluphenazine decanoatc","volume":"1978","author":"Kane J.","year":"1978","journal-title":"Am J Psychiatry"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)91017-6"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.3109\/03602537808993787"}],"container-title":["Acta Psychiatrica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0447.1985.tb08536.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0447.1985.tb08536.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T15:39:33Z","timestamp":1737387573000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0447.1985.tb08536.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1985,7]]},"references-count":12,"journal-issue":{"issue":"S322","published-print":{"date-parts":[[1985,7]]}},"alternative-id":["10.1111\/j.1600-0447.1985.tb08536.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0447.1985.tb08536.x","archive":["Portico"],"relation":{},"ISSN":["0001-690X","1600-0447"],"issn-type":[{"type":"print","value":"0001-690X"},{"type":"electronic","value":"1600-0447"}],"subject":[],"published":{"date-parts":[[1985,7]]}}}